Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 05/17/2013

Company Name Symbol %Change
VIASAT INC VSAT
19.35%
OLD SECOND B OSBC
5.76%
GAMCO INVEST GBL
4.61%
CORNING INC GLW
4.47%
SYNCHRONOSS SNCR
4.23%
 

TODAY'S TOPICS

1. ZACKS RANK BUY STOCKS: Today we highlight four new stocks with a short-term "Buy" or "Strong Buy" recommendation: SiRF Technology (SIRF), Harley-Davidson (HOG), AG Edwards (AGE) and Morgan Stanley (MS). Get these stories below.

2. PROFIT TRACKS – EARNINGS AND MARGINS: If you are searching for earnings growth and net profit margins, check out this screening strategy.

3. ZACKS EQUITY RESEARCH: Advances in medical technology, coupled with the aging of the population, support a positive long-term view of the health sector overall. Read the Analyst Interview and get our Bull and Bear Stocks of the Day.

4. OPTIONS CENTER: The experts at Schaeffer’s highlight a Brazilian bank with an impressive long-term picture that has fallen victim to excessive pessimism toward the financial sector.

5. BEST OF THE ZACKS $100,000 CHALLENGE: ‘Danny1992’ is going to use a new strategy for the Zacks Challenge. Learn more in this Simulator participant’s blog post, along with two competitors.

- - - - - - - - - - - - - - - - - - - - -

"SNiP Technique" now used in EVERY major hospital – could make early investors 1,500% It’s not a drug or pill, but a new FDA-approved technology that could lower your blood pressure and even prevent Alzheimer’s. The Economist says it "will revolutionize the entire healthcare system."

It's already brought some investors returns of 1,500% - but the biggest gains are still to come...

Click for full details.

Tuesday - June 26, 2007

Want to view the archive of past issues? Click here.

Manage Profit from the Pros subscription:

1. ZACKS RANK BUY STOCKS

Back to top

Zacks #1 Ranked stocks average a 31.9% annual return. Every day on Zacks.com we highlight four new Zacks Rank Buy stocks. Each individual stock is chosen based on how well they match the criteria for the four main schools of investing: Aggressive Growth, Momentum, Growth & Income and Value.
 

Aggressive Growth – SiRF Technology (SIRF)

SiRF Technology (SIRF) will purchase Centrality Communications Inc. for $283 million in stock and cash. SiRF said in a regulatory filing that the exact mix of stock and cash would be determined just prior to closing. The boards of directors of both companies have approved the deal, which is expected to close in the third quarter. Read the full analysis on SIRF now!

 
Growth & Income - Harley-Davidson (HOG)

On Jun 15, Harley-Davidson's (HOG) stock got a lift last Friday due to speculation that Honda may be looking to acquire the company. Several analysts and the parties involved denied denied the rumors. Read the full analysis on HOG now!

 
Momentum - AG Edwards Inc. (AGE)

Listen to the audio podcast on AGE through Zacks' NEW Audio Feature.

AG Edwards Inc. (AGE) reported first-quarter earnings of $1.18 per share, up from $1.01 last year and nine cents above expectations. Revenues rose to $842 million from $765 million in the year-ago period. While commission revenue fell 3%, investment banking revenues surged 108% to $52 million due to higher underwriting and fee revenue. Last month, Charlotte-based Wachovia announced plans to buy A.G. Edwards for $6.8 billion and merge the St. Louis-based brokerage with Wachovia Securities. AGE has returned over 21% since being featured as a Momentum play. Read the full analysis on AGE now!

 
Value - Morgan Stanley (MS)

On Jun 12, Morgan Stanley (MS) reported second-quarter earnings of $2.45 per share, up from $1.85 in the year-ago period and 60 cents above expectations. Driving the earnings growth, revenues rose an amazing 32% to a record $11.5 billion, also beating analysts’ estimates of $10.03 billion. Record revenues from equity sales and trading and investment banking contributed heavily to the quarter’s performance. Meanwhile, the soon to be spun-off Discover unit posted a 38% decline in pre-tax income from year-ago numbers. Read the full analysis on MS now!

 
Zacks Rank Resources

  • Zacks Rank Homepage: Go there now.
     
  • Zacks Momentum Trader: Discover the best Zacks #1 Ranked momentum stocks to buy now. Learn more...
     
  • Zacks Rank Breakout Trader: When a stock moves quickly to a Zacks #1 Rank, this trading service uses that turnaround to make 55% a year. Learn more...
     
  • Zacks Options Trader: Combine the timeliness of Zacks #1 Rank stocks with the explosive profit potential of options. Learn more...
     
  • Zacks Wealth Management: Own all the Zacks #1 Ranked stocks in a portfolio managed by Zacks. Learn more...

 
ZACKS REVEALS THE MOST EFFECTIVE WAY TO BENEFIT FROM #1 RANK STOCKS

Learn how in your FREE Investment Kit.

Inside we will describe how you can invest in ALL the Zacks #1 Rank Stocks. From 2002 through Q1 2007, this portfolio has outperformed the S&P 500 by a staggering 55.3%! We would like to offer you this FREE KIT with details on this time tested philosophy as well as information on four other strategies.

Click Here for Your FREE ZACKS INVESTMENT KIT.
 

2. PROFIT TRACKS

Back to top

Zacks.com is proud to share with you some of the best trading strategies that truly allow you to Profit from the Pros. Today we highlight...
 

Profit Tracks: Earnings and Margins

This Profit Track goes to the heart of fundamental investing by finding companies with healthy earnings. The main ingredients are the search for Earnings Growth and Net Profit Margins. Then for good measure we make sure earnings estimates are moving higher which is a strong indicator of future performance and that brokerage firms are positively rating the stock.

Here are four stocks that make the grade for the Earnings and Margins Profit Track:

American Oriental Bioengineering Inc. (AOB) sports earnings per share growth of 48% for the most recently completed year, versus the year-prior. The company offers a net margin of 0.27. AOB recently announced the signing of a letter of intent to acquire Changchun Xinan Pharmaceutical Group Company Limited (CCXA), a privately owned plant based pharmaceutical company. In early May, the company posted first-quarter earnings of 10 cents per share, beating last year's eight cents and matching the consensus estimate. Read the full analysis on AOB now!
 

Dynamex Inc. (DDMX) reported fiscal third-quarter earnings of 32 cents per share in early June. The result matched the consensus estimate and outperformed the year-ago total. Sales increased 19.1% from the prior year quarter. DDMX meets the criteria of this Profit Track as evidenced by its net margin of 0.04 and year-over-year earnings growth of 17%. Read the full analysis on DDMX now!
 

PMA Capital Corp. (PMACA) released first-quarter earnings of 10 cents per share in early May. The results topped the consensus estimate by 43% and surpassed the previous year’s total. Direct premiums written for the first quarter of 2007 were up by 26%, compared to last year’s first quarter. PMACA experienced annual earnings per share growth of 120% from the year-prior. Read the full analysis on PMACA now!
 

Universal Stainless & Alloy Products, Inc. (USAP) saw annual earnings per share growth of 50% for the most recent full year, versus the year-prior. The company’s net margin stands at 0.10. In late April, Universal Stainless & Alloy Products announced a record $1.00 per share for first-quarter earnings. The result beat the consensus estimate by 18% and was ahead of last year’s first-quarter performance. USAP stated that its record first quarter shows the ongoing benefit of the company’s investments in equipment and personnel over the past two years, which have enabled USAP to respond to strong end markets and continue its shift to higher value-added products while also improving its on-time delivery performance. Read the full analysis on USAP now!
 

To see the full list of stocks that currently pass this winning screen, click here.

All the Profit Track strategies were created and backtested using the Research Wizard software from Zacks Investment Research. If you like this screening strategy, but want to narrow down the list of stocks and even improve the performance, then you should start a free trial to this powerful stock picking tool. Learn more about the Research Wizard free trial offer and our new special report “Top 10 Stock Screening Strategies”.

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

 
SCREEN OF THE WEEK

New Analyst Coverage

Kevin Matras explains why a good stock screener can be your best tool for picking options. More...
 


3. ZACKS EQUITY RESEARCH

Back to top

When we asked a few questions of Zacks senior Health Care analyst Chris Kallos recently, we were interested to find out where the strengths lie in this group these days, as well as over the longer-term.

With relatively new government programs still keeping the Health Care industry in flux, how did your coverage perform overall in the first quarter?

For the most part, 1Q07 produced slightly better-than-expected earnings amongst the HMO group, driven by solid growth of respective Medicare businesses, which managed to offset continuing weakness in the commercial segment in some cases.

More. . .

 
Great minds like a think.
Try 6 Risk-Free Issues of The Economist!

If you like The Economist, you'll continue to receive 18 additional Issues (24 in all) for just $49.90. If you decide The Economist is not for you, simply write cancel on your invoice, return it and the free trial issues are yours to keep. U.S. and New Subscribers Only. http://at.zacks.com/?id=3762
 

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Back to top

 
Zacks Equity Research continued...

Are you looking for something similar to Q1 performance in Q2? Where are you looking for the biggest changes?

In recent days, seven of the largest health insurers, which included Humana (HUM) and Coventry (CVH), agreed to suspend marketing of some plans to seniors amidst allegations of misleading and aggressive sales practices. Under the voluntary agreement, the companies won't promote private so-called fee-for-service plans until Medicare officials certify they use accurate and appropriate disclaimer language.

That said, we believe the impact to 2Q07 earnings will be minimal. In 1Q07, we noted a slight increase in medical loss ratios overall (medical costs as a percentage of premium revenue) amongst HMOs, and as a result will be focusing attention on this key metric for 2Q07.

Lots of people have begun to look at the Health Care sector long-term. Where are its biggest areas of strength in the short-to-medium term?

In our opinion, advances in medical technology, coupled with aging of the population, support a positive long-term view on the health sector overall. That said, given the aging of the population, and rising health care costs, financing care for future beneficiaries remains a challenge for government. Cost containment remains a central issue going forward, and given government initiatives such as Medicare Part D, one well suited for outsourcing to third party administrators such as managed care organizations. Notwithstanding the upcoming U.S. presidential race and associated health care rhetoric, we anticipate investor sentiment in the short term to be driven by the final 2008 Budget health care rulings and further articulation of the Bush Administration’s “Affordable Choices” initiative announced in the State of the Union address earlier this year.

To read the complete Analyst Interview, click here.

Chris Kallos is a senior analyst covering the Health Care industry for Zacks Equity Research.

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Back to top

 
MORE FROM ZACKS EQUITY RESEARCH…

 
Analyst Blog

Real-time market insights from Zacks Equity Research Analysts. Stocks featured recently include Goodyear Tire (GT), Colgate-Palmolive (CL), Johnson & Johnson (JNJ) and UST, Inc. (UST). Get their latest posts: click here.

 
ECONOMIC OUTLOOK

Fed to Leave Rates Unchanged

Reviving growth and an expected decline in inflation will allow the Fed to leave rates unchanged. More...

 
BULL OF THE DAY

UBS A.G. (UBS) - Impressive Strength Continues. For full Zacks research report, click here.

 
BEAR OF THE DAY

Align Technologies (ALGN) - Saturated Market. For full Zacks research report, click here.

 
EARNINGS PREVIEW

Listen to the audio podcast for the Earnings Preview through Zacks' NEW Audio Feature.

The Week of June 25 – June 29

Interest rates will remain the primary focus this week with the Fed meeting on Wednesday and Thursday. More...

 
Rating Upgrades - NEW! 

Find out which stocks have been recently upgraded by Zacks Equity Research: click here.

 
Zacks Equity Research Buys - NEW! 

Read the reports on all of the stocks on the Zacks Equity Research Buy List: click here.


 
Learn More about Zacks Equity Research at: Click here.

Full access to Zacks Equity Research reports is only available on Zacks.com. : Click here.

Zacks Wealth Management: Own all the Zacks #1 Ranked stocks in a portfolio managed by Zacks. Learn more...
 


4. OPTIONS CENTER

Back to top

Zacks has partnered with the leading options experts, Schaeffer's Investment Research, to provide you the best options commentary, research, and trading tools on the market today.

Free Online Options Research.

Zacks/Schaeffer’s Options Trading service.

 
Here is this week's article on how Schaeffer's Tools can help you Profit with Options.

After checking in with the Zacks High Open Interest Call Position filter last week, I decided to check back with a favorite filter of mine - the Put/Call Ratio Greater than 1.0 filter - to see what stocks face heavy pessimism from options players.

A put/call open interest ratio is simply the ratio of total put open interest to total call open interest. We compute Schaeffer's put/call open interest ratio (SOIR) based on open interest in the front three months only. These near-term options tend to attract a more speculative crowd, the sentiment of which is more useful for shorter-term trading.

After many tries, I finally found an interesting subject for today’s trading tools observation in the form of Banco Bradesco (BBD). You may wonder, who is BBD? Good thing, because I was wondering as well. According to Hoover’s, BBD is a no-frills bank that prides itself on serving low- and medium-income individuals in Brazil since the 1960s. BBD is the country’s largest private-sector bank, boasting 3,000 banking branches and is a leader in insurance and pension management. BBD also offers savings plans, leasing, auto financing, and credit card services. The firm also has offices that serve Brazilian residents and businesses in Argentina and Japan. Bradesco Securities U.S. operates in New York City, and Banco Bradesco Luxembourg provides private banking services.

Before we dive any deeper into technicals and sentiment, a little background is in order. What is the filter? Well, let’s first define a put and a call. A put is simply a bet that the underlying stock is going to move lower, while a call is a bet that the underlying stock is going to move higher. According to our Expectational Analysis® methodology, heavy attention paid to calls by investors indicates an increase in optimism toward an equity, and can present the opportunity for a solid bearish addition to your portfolio.

Before looking at BBD specifically, let’s address our Schaeffer’s methodology. We are contrarian-based investors, indicating that we want to see skepticism toward an outperforming stock. On the other hand, we typically like to see optimism toward an underperformer. In our eyes, too much optimism is a sign that nearly everyone who wants to invest in a particular stock already has. Just because a stock sees substantial optimism doesn’t mean that we will blindly short that particular security; we need to see some negative price action or a major catalyst for a downside move in order to pull the trigger in most cases. Other indicators we tend to use to measure overall sentiment include short interest, magazine cover stories, media comments, and analyst ratings.

Technically, BBD’s performance can be classified as outstanding. Since hitting a low of 2.91 back in May 2004, the stock has added more than 750%. Yes, ladies and gentlemen, that is a 7, a 5, and a 0 to make 750. A major technical reason for the impressive gain is BBD’s 10-week and 20-week moving averages. Since June 2004, the equity has finished below these trendlines 11 times, and all during the span of May to July 2006. The stock continues to advance, as does its 10-week and 20-week moving averages. The former has provided a floor to the recent pullback, acting as support in each of the past two weeks.

The long-term picture for BBD is as impressive, as its all-time nadir checks in at 1.61. Plugging that number into the same equation from before, we see that the stock has gained some 1,444%. Nice growth…

BBD’s 10-month and 20-month moving averages have provided support various times throughout this impressive run higher. In fact, the last time the equity finished a month below this dynamic duo was February 2003. Now, the 10-month trendline is a bit far away (it is working its way through the 20 region while the stock trades at 24.86), but it also appears that the stock has found support at the 24 level.

Apparently, pessimism toward the financial sector is blinding the options players when it comes to BBD. Now, the options are lightly traded, nonetheless, puts outnumber calls more than 4-to-1 in the front 3-month option series, resulting in a SOIR of 4.36. This reading is higher than all of those taken during the past 52 weeks, indicating that pessimism runs at extreme levels. This reading suggests that there is ample room for buying pressure to creep into the picture for BBD, which could serve to push the stock higher.

According to Zacks, BBD is also a little light when it comes to analyst coverage. Only three brokerages follow the firm, deeming it worthy of one “strong buy,” and two “holds.” This configuration is a good bullish contrarian indicator, as it leaves the door open for upgrades and/or positive initiation; both of which could push the stock higher still.

Make sure to continue utilizing all of the valuable filters on these pages for more money-making ideas. Moreover, don't be afraid to make a few paper trades in order to see what strategy works best for you. Please remember that, when it comes to options, the majority of your trades are going to be losers. Don't get discouraged, because that's the beauty of the leverage that options provide. It takes only a few winners out of every 10 trades to make you a very happy investor. Thanks for reading, and best of luck in your trading!

To learn more about the Unusually High Volume Calls filter, click here.

Discover all the tools and commentary available from the Zacks.com Options Center.

 
Zacks Rank + Options = Trading Success!

Leverage the timeliness of Zacks #1 Rank stocks with options trades that maximize profits and minimize risks. Learn more about our new Options Trading service.


5. Best of the Zacks $100,000 Challenge

Back to top

Zacks is conducting a nationwide talent search to find the very best stock pickers. The winner gets a $100,000 dream job with Zacks! . Sign up for free to join the competition, or just read what stocks the leading players are trading on the Zacks Challenge Player Blogs.
 

Best of the Zacks Challenge Player Blogs

Here's what the leading players are saying lately:
 

Danny1992 (Rank #32 with $146,178

NEW STRATEGY FOR ZACKS (NYX, GMR)
I’m going to use a new strategy for the Zacks game. I realized my strategy was wrong. I’m going to keep my stocks for months. All stocks move in the long-term. I’m going to keep…

Read More or Comment on this post.
 

Java J

>> JAVA’S MARKET MUSINGS #80 <<
I believe that the 20SMA is going to start functioning as resistance to the market… we have not yet seen a great deal of evidence of this occurring yet, but the negative expansion bars taking the market down below the 20 SMAs is definitely a bearish sign… I continue to note that the slope of the MACD remains convincingly negative…

Read More or Comment on this post.
 

Clark2005

TUBR TUBEAROO IS GETTING UP (TUBR)
Tubearoo is sneakily going up and its price is trading up for nine days in a row. And the trading volume is increasingly gathering momentum…

Read More or Comment on this post.
 

Read all the Player Blog posts.


OTHER TOOLS FROM ZACKS

Back to top

At the heart of Zacks Investment Research is the Zacks Rank investment philosophy that continues to vastly outperform the market. Our Zacks #1 Ranked (Strong Buys) have produced the following results for investors:

  • +31.9% average annual return since 1988 versus +11.9% for S&P 500
  • +43.8% total return from 2000 to 2002 - the worst bear market in over 60 years.
  • +23.7% in 2006 and +17.8% in 2005

And just as importantly, the Zacks #5 Rank stocks (Strong Sell) List has alerted investors as to which stocks to dump from Their portfolios to avoid unnecessary losses.

To truly take advantage of the Zacks Rank, you need to first understand how it works. That's why we created the free special report: Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions. Download a free copy now to prosper in the years to come.

Or view the full list of Zacks #1 Rank stocks.

FREE PORTFOLIO TRACKER

Do you believe that these events affect stock prices?

  • Broker Recommendation changes
  • Earnings Estimate revisions
  • Earnings Surprises

If you answered yes, then how are you staying on top of these changes for your stocks? If you are one of the 55,000 investors who wake up every morning to the Daily Portfolio Updates emails from Zacks.com, then you are all set. If not, then sign up now to get this vital information sent to you daily to help take definitive action to improve your portfolio's performance.

Did we mention it's free? Get started now!


We hope you enjoyed this issue of "Profit from the Pros", And we look forward to visiting with you again next week.

REFER-A-FRIEND

If you enjoy this e-mail newsletter, then please pass it along to a friend. Simply forward them the link below to sign up for their own free subscription. If you're reading a forwarded copy, sign up for your own, so you get this wealth of information every week. Just click here. THANKS!

Regards and Happy Investing,

Charles Rotblut, CFA

Senior Market Analyst
Zacks.com

p.s. What is the mission for Zacks Profit from the Pros? Click here to find out how we will help you become a more successful investor.


*Zacks Rank performance is the total return (price changes + dividends) of equal weighted portfolios, consisting of those stocks with the indicated Zacks Rank, assuming zero transaction costs. These returns are not the result of a backtest; these are actual returns since 1988. The stocks in the Zacks Rank portfolios were available to Zacks clients before the beginning of each month (monthly rebalancing). Performance results from 1988 through September 2006 are based on a subset of all Zacks Rank stocks that excludes stocks covered by only one analyst and ADR’s.

The S&P 500 Index is a well-known, unmanaged index of the prices of 500 large-company common stocks, mainly blue-chip stocks, selected by Standard & Poor's. The S&P 500 Index assumes reinvestment of dividends but does not reflect advisory fees. An investor cannot invest directly in an index.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

To contact us by mail:

Zacks Investment Research
Attn: Profit from the Pros
111 N. Canal St., Suite 1101
Chicago, IL 60606

To unsubscribe from receiving "Profit from the Pros" e-mail newsletter, click here.


 

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.